Amneal Pharmaceuticals, Inc. (AMRX)

Market Cap	1.68B
Revenue (ttm)	2.39B
Net Income (ttm)	-83.99M
Shares Out	308.55M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	10.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,793
Open	5.41
Previous Close	5.37
Day's Range	5.36 - 5.47
52-Week Range	1.65 - 6.46
Beta	1.35
Analysts	Strong Buy
Price Target	7.31 (+34.01%)
Earnings Date	May 3, 2024

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 7,700
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRX

Financial Performance

In 2023, AMRX's revenue was $2.39 billion, an increase of 8.20% compared to the previous year's $2.21 billion. Losses were -$83.99 million, -35.38% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price forecast is $7.31, which is an increase of 34.01% from the latest price.

Price Target

$7.31

(34.01% upside)

Analyst Consensus: Strong Buy